EyePoint Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
&-
Good morning, everyone. Thank you for joining the EyePoint Pharmaceuticals presentation on day three of the JPMorgan Healthcare Conference. I'm [Wanhee Yeo], from the JPMorgan Healthcare Investment Banking team. And it's my pleasure to be introducing you to Dr. Jay Duker, President and Chief Executive Officer of EyePoint Pharmaceuticals.
Thank you very much, and thanks all for coming and listening this morning. We are a publicly traded company. And as such, I will be making some forward-looking statements. And if you need any more information on that, please feel free to visit our website.
EyePoint in its heart is a drug delivery company to the back of the eye. Our lead product is called EYP-1901. It's a combination of vorolanib, which is a small molecule tyrosine kinase inhibitor that has activity against all the VEGF receptors and is placed into our patented Durasert E delivery system. E is for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
